| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, ErbB-2 | 12 | 2025 | 496 | 2.920 |
Why?
|
| Breast Neoplasms | 21 | 2025 | 2483 | 2.750 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2025 | 714 | 1.370 |
Why?
|
| Trastuzumab | 9 | 2025 | 139 | 1.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 1250 | 0.990 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2011 | 25 | 0.870 |
Why?
|
| NF-kappa B | 6 | 2011 | 462 | 0.850 |
Why?
|
| Curcumin | 3 | 2011 | 41 | 0.820 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 1885 | 0.770 |
Why?
|
| Azadirachta | 2 | 2011 | 2 | 0.770 |
Why?
|
| Signal Transduction | 16 | 2025 | 4524 | 0.760 |
Why?
|
| Plant Extracts | 2 | 2011 | 118 | 0.690 |
Why?
|
| Estrogen Receptor alpha | 4 | 2021 | 449 | 0.650 |
Why?
|
| Neuroblastoma | 4 | 2011 | 511 | 0.640 |
Why?
|
| Apoptosis | 6 | 2019 | 1792 | 0.620 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 321 | 0.590 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 1682 | 0.570 |
Why?
|
| Gamma Rays | 3 | 2011 | 49 | 0.550 |
Why?
|
| Biomarkers, Tumor | 7 | 2023 | 1431 | 0.530 |
Why?
|
| Gene Fusion | 1 | 2016 | 55 | 0.520 |
Why?
|
| Radiation, Ionizing | 2 | 2011 | 42 | 0.460 |
Why?
|
| Carrier Proteins | 2 | 2020 | 1024 | 0.440 |
Why?
|
| Cell Line, Tumor | 14 | 2021 | 3299 | 0.410 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 326 | 0.410 |
Why?
|
| Rosaceae | 1 | 2011 | 1 | 0.390 |
Why?
|
| Molecular Targeted Therapy | 4 | 2025 | 353 | 0.390 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2025 | 520 | 0.390 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 53 | 0.380 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 74 | 0.370 |
Why?
|
| Quinazolines | 3 | 2023 | 175 | 0.370 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 102 | 0.370 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 141 | 0.360 |
Why?
|
| Digestive System | 1 | 2010 | 60 | 0.360 |
Why?
|
| Genes, p53 | 1 | 2010 | 215 | 0.340 |
Why?
|
| Sarcoma, Ewing | 1 | 2010 | 113 | 0.330 |
Why?
|
| Receptors, Estrogen | 5 | 2021 | 789 | 0.330 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 1680 | 0.320 |
Why?
|
| Gene Amplification | 3 | 2019 | 228 | 0.320 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2020 | 197 | 0.320 |
Why?
|
| Mice, Nude | 4 | 2020 | 697 | 0.310 |
Why?
|
| Genomics | 1 | 2016 | 1472 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 672 | 0.300 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 538 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 342 | 0.270 |
Why?
|
| Female | 21 | 2025 | 65361 | 0.260 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 688 | 0.250 |
Why?
|
| Protein Kinases | 2 | 2016 | 330 | 0.240 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 372 | 0.230 |
Why?
|
| Humans | 28 | 2025 | 122971 | 0.230 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2011 | 69 | 0.210 |
Why?
|
| Cell Survival | 4 | 2021 | 817 | 0.210 |
Why?
|
| Prognosis | 5 | 2021 | 4503 | 0.200 |
Why?
|
| Remission Induction | 2 | 2020 | 301 | 0.200 |
Why?
|
| Linear Energy Transfer | 2 | 2011 | 7 | 0.190 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 1229 | 0.190 |
Why?
|
| Plant Leaves | 2 | 2011 | 43 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 37 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 53 | 0.180 |
Why?
|
| Mice | 9 | 2021 | 17647 | 0.180 |
Why?
|
| Pyrimidinones | 1 | 2020 | 40 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 880 | 0.180 |
Why?
|
| Pyridones | 1 | 2020 | 111 | 0.170 |
Why?
|
| Mevalonic Acid | 1 | 2019 | 18 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 213 | 0.170 |
Why?
|
| Pyridines | 1 | 2021 | 222 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 254 | 0.160 |
Why?
|
| Piperazines | 1 | 2021 | 227 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 106 | 0.160 |
Why?
|
| Cinnamates | 1 | 2018 | 15 | 0.160 |
Why?
|
| Brain | 1 | 2010 | 2961 | 0.160 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 98 | 0.160 |
Why?
|
| Lymphocytes | 1 | 2019 | 404 | 0.150 |
Why?
|
| Oncogene Addiction | 1 | 2017 | 3 | 0.150 |
Why?
|
| Indoles | 1 | 2018 | 182 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 762 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2019 | 312 | 0.140 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 570 | 0.140 |
Why?
|
| Animals | 9 | 2021 | 33923 | 0.140 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 1703 | 0.130 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 664 | 0.130 |
Why?
|
| Gene Expression | 1 | 2020 | 1592 | 0.120 |
Why?
|
| Genomic Instability | 1 | 2016 | 230 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 1073 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 492 | 0.120 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 115 | 0.120 |
Why?
|
| Cell Proliferation | 3 | 2018 | 2321 | 0.120 |
Why?
|
| Open Reading Frames | 1 | 2014 | 212 | 0.110 |
Why?
|
| Radiation Tolerance | 2 | 2011 | 53 | 0.110 |
Why?
|
| Cell Separation | 1 | 2014 | 240 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1689 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5025 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 282 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 606 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2023 | 12083 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2011 | 3 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 2060 | 0.100 |
Why?
|
| Aniline Compounds | 1 | 2011 | 19 | 0.100 |
Why?
|
| Aminoquinolines | 1 | 2011 | 35 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2014 | 811 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 13 | 0.100 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2011 | 34 | 0.100 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 376 | 0.100 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1222 | 0.100 |
Why?
|
| I-kappa B Proteins | 1 | 2011 | 41 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 524 | 0.090 |
Why?
|
| Time Factors | 2 | 2011 | 6216 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 865 | 0.090 |
Why?
|
| Infrared Rays | 1 | 2010 | 20 | 0.090 |
Why?
|
| Cell Movement | 1 | 2014 | 838 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 70 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2011 | 285 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1760 | 0.090 |
Why?
|
| Fruit | 1 | 2011 | 216 | 0.090 |
Why?
|
| Telomerase | 1 | 2011 | 167 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 174 | 0.090 |
Why?
|
| DNA Primers | 1 | 2010 | 669 | 0.080 |
Why?
|
| Transfection | 1 | 2011 | 1076 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 483 | 0.080 |
Why?
|
| Phenotype | 2 | 2016 | 4222 | 0.080 |
Why?
|
| Tamoxifen | 2 | 2020 | 363 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1302 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2011 | 2833 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 222 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1247 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1598 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 653 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2021 | 1617 | 0.070 |
Why?
|
| Base Sequence | 1 | 2010 | 3118 | 0.070 |
Why?
|
| DNA | 1 | 2011 | 1608 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3084 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1440 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2010 | 804 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 501 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 1287 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 999 | 0.050 |
Why?
|
| Mutation | 2 | 2017 | 5794 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4392 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2016 | 874 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 83 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 85 | 0.040 |
Why?
|
| Dasatinib | 1 | 2020 | 42 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2020 | 91 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 71 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 67 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 351 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 214 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 320 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2009 | 131 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 163 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 366 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 183 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 6 | 0.030 |
Why?
|
| Estradiol | 1 | 2018 | 534 | 0.030 |
Why?
|
| Estrogens | 1 | 2018 | 507 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1473 | 0.030 |
Why?
|
| Middle Aged | 3 | 2020 | 25885 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 238 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 147 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 619 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 999 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 517 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2824 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 61 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 18998 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 243 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 303 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4308 | 0.020 |
Why?
|
| Genome, Human | 1 | 2016 | 1261 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1583 | 0.020 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2009 | 5 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2009 | 9 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 44 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 28944 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6343 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 245 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 677 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 1354 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 351 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 8830 | 0.020 |
Why?
|